
Sign up to save your podcasts
Or
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.
4.5
303303 ratings
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.
30,975 Listeners
1,011 Listeners
1,773 Listeners
30,269 Listeners
111,073 Listeners
485 Listeners
124 Listeners
386 Listeners
60 Listeners
88 Listeners
31 Listeners
146 Listeners
11 Listeners
45 Listeners
368 Listeners